© Reuters. FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California January 11, 2016. REUTERS/Mike Blake/File Photo
WASHINGTON (Reuters) – Illumina Inc (NASDAQ:) filed an appeal late on Monday against an order by the U.S. Federal Trade Commission, which is demanding that the company divest cancer diagnostic test maker Grail Inc because of concern that its ownership would stifle competition in the U.S. market for cancer tests.
Operator Good day, and thanks for standing by. Welcome to the This autumn and year-end 2025 Monetary Outcomes NanoXplore Earnings...
This text was written byObserveInfrastructure Capital Advisors ("Infrastructure Capital") is a number one supplier of funding administration options designed to...
This text was written byObserveFred Alger Administration, LLC (“Alger”) is a privately held $27.4 billion development fairness funding supervisor. Alger...
Charli D’Amelio posted her first TikTok at 15. Quick-forward a couple of years and she or he’s incomes tens of...
Antonio RealeBofA Securities, Analysis Division We're enjoying on dwelling floor actually. So a heat welcome to our personal group CFO,...
That is the discussion board for day by day political dialogue on In search of Alpha. A brand new model...
Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.
